Clinical trials: Hemostatic Disorders
Neoplasms
Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma
This trial will evaluate safety, tolerability, and efficacy of letetresgene autoleucel (GSK3377794) with or without pembrolizumab in participants with relapsed and refractory multiple myeloma.
- Trial name
- NCT03168438
- Testing
- Letetresgene autoleucel, Letetresgene autoleucel with pembrolizumab, Fludarabine
- Where
- 5 sites in United States
- Volunteers
- 6 people
- Sponsor
- GlaxoSmithKline
Multiple Myeloma
Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma
This study is designed as a phase I-II, open label, dose finding study. Study treatment will be as follows, in 28 day cycles: Pomalidomide: once daily orally (PO) dosing on days 1-21, every 28 days Bendamustine: once…
- Trial name
- NCT01754402
- Testing
- Bendamustine, Pomalidomide, Dexamethasone
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Cristina Gasparetto
Multiple Myeloma, Non-Hodgkin's Lymphoma
A Study Evaluating a Proprietary Amino Acid Mixture (Enterade®) in Patients Receiving High-Dose Melphalan Conditioning Followed by Autologous Stem Cell Transplantation for Multiple Myeloma and Non-Hodgkin Lymphoma
This research study is evaluating Enterade, a supplement, as a possible treatment for the side effects caused by Stem Cell Transplant.
- Trial name
- NCT02919670
- Testing
- Enterade, Standard Supportive Care
- Where
- United States
- Volunteers
- 114 people
- Sponsor
- Dana-Farber Cancer Institute
Relapsed or Refractory Multiple Myeloma
Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074)
The purpose of this Phase I study of vorinostat in combination with lenalidomide and dexamethasone in participants with relapsed or refractory multiple myeloma is to determine the maximum tolerated dose (MTD) as estimated by the…
- Trial name
- NCT00642954
- Testing
- Vorinostat, Lenalidomide, Dexamethasone
- Volunteers
- 31 people
- Sponsor
- Merck Sharp & Dohme LLC
Myeloma
Intervention for Symptom Burden During Maintenance Therapy for Multiple Myeloma
The goal of this clinical research study is to learn if minocycline can help reduce the symptoms reported by patients with MM who receive therapy with lenalidomide.
- Trial name
- NCT01793051
- Testing
- Minocycline, Questionnaires
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)
The study is designed as a Phase II, multicenter trial of vaccination with Dendritic cell/myeloma fusions with granulocyte macrophage colony-stimulating factor (GM-CSF) adjuvant plus lenalidomide maintenance therapy versus…
- Trial name
- NCT02728102
- Testing
- Tumor Cell Collection, Autologous Stem Cell Transplant, Melphalan
- Where
- 15 sites in United States
- Volunteers
- 203 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Multiple Myeloma
MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
This was an open-label, single-arm, pilot study of the recombinant MAGE-A3 protein plus the immunological adjuvant AS15 (recMAGE-A3 + AS15) in subjects with symptomatic multiple myeloma who had completed induction therapy with at…
- Trial name
- NCT01380145
- Testing
- recMAGE-A3 Protein + AS15 Adjuvant
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- Ludwig Institute for Cancer Research
Chronic Idiopathic Thrombocytopenic Purpura
A Study to Find How Safe and Effective GAMMAPLEX® is in Subjects With Chronic Idiopathic Thrombocytopenic Purpura (ITP)
To determine if GAMMAPLEX raises the platelet count of subjects with chronic ITP to a threshold of 50 x 109/L, similar to that of published response >60%.
- Trial name
- NCT00504075
- Testing
- Gammaplex, intravenous immunoglobulin
- Where
- 30 sites in United States, Argentina and 1 more
- Volunteers
- 35 people
- Sponsor
- Bio Products Laboratory
Multiple Myeloma
A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma
The purpose of this study is to evaluate complete response plus (+) very good partial response (CR+VGPR) rate following 4 cycles of induction therapy of daratumumab in combination with cyclophosphamide, bortezomib, and…
- Trial name
- NCT02951819
- Testing
- Daratumumab, Cyclophosphamide, Bortezomib
- Where
- 26 sites in United States
- Volunteers
- 101 people
- Sponsor
- Janssen Scientific Affairs, LLC
Waldenström's Macroglobulinemia
Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia
The purpose of this study is to evaluate the safety and efficacy of ibrutinib in combination with rituximab in participants with Waldenström's macroglobulinemia (WM).
- Trial name
- NCT02165397
- Testing
- Ibrutinib, Rituximab
- Where
- 48 sites in United States, Australia and 7 more
- Volunteers
- 181 people
- Sponsor
- Pharmacyclics LLC.
Relapsed/Refractory Multiple Myeloma
Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma
This study will test the safety of ipilimumab to see what effects, if any, the drug has when used as maintenance therapy for people with relapsed/refractory multiple myeloma who have received chemotherapy and allogeneic…
- Trial name
- NCT04635735
- Testing
- Ipilimumab
- Where
- 7 sites in United States
- Volunteers
- 3 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Idiopathic Thrombocytopenic Purpura, Thrombocytopenia
An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP
This protocol will provide open label romiplostim to adult thrombocytopenic subjects. Romiplostim will be administered by subcutaneous injection once per week.
- Conditions
- Idiopathic Thrombocytopenic Purpura, Thrombocytopenia, Thrombocytopenic Purpura
- Trial name
- NCT00508820
- Testing
- Romiplostim
- Volunteers
- 407 people
- Sponsor
- Amgen
Myomectomy; Surgical Blood Loss
Rectal Misoprostol as a Hemostatic Agent During Abdominal Myomectomy
Purpose is to identify if misoprostol in addition to local vasopressin decreases blood loss when compared to vasopressin alone, which is our current practice at this time.
- Trial name
- NCT03064568
- Testing
- Misoprostol 200Mcg Tab
- Where
- 3 sites in United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Multiple Myeloma
A Safety Confirmation Study on Lenalidomide With Dexamethasone In Japanese Patients With Previously Treated Multiple Myeloma
To evaluate the safety and efficacy of lenalidomide with dexamethasone in Japanese patients with previously treated multiple myeloma.
- Trial name
- NCT00928486
- Testing
- Lenalidomide, Dexamethasone
- Where
- 8 sites in Japan
- Volunteers
- 25 people
- Sponsor
- Celgene
Cancer-related Problem/Condition, Depression
Programmed Environmental Illumination (PEI) of Hospital Rooms to Prevent/Reduce Cancer-Related Fatigue
A sample of 60 patients scheduled for HSCT in the treatment of MM will be recruited in the weeks to months prior to their hospitalization.
- Conditions
- Cancer-related Problem/Condition, Depression, Circadian Rhythm Disorders
- Trial name
- PEI (NCT03198754)
- Testing
- PEI Experimental Light, Comparison Light
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Multiple Myeloma
A Study of Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Untreated Multiple Myeloma and Planned for a High Dose Chemotherapy
The purpose of this study is to evaluate the safety and effectiveness of bortezomib in combination with a standard regimen of cyclophosphamide and dexamethasone.
- Trial name
- NCT00833560
- Testing
- Cyclophosphamide, Bortezomib, Dexamethasone
- Where
- 34 sites in Germany
- Volunteers
- 401 people
- Sponsor
- Janssen-Cilag G.m.b.H
Gastric Ulcer, Duodenal Ulcer, Acute Stress Gastritis, and Acute Gastric Mucosal Lesions
Lansoprazole Intravenous 30 mg Specified Drug-use Survey [Hemostatic Effect/Rebleeding Rate]
The purpose of this survey is to evaluate the safety (i.e., frequency of adverse events) and efficacy (i.e., hemostatic effect, rate of rebleeding after confirmation of hemostasis) of administration of lansoprazole intravenous 30…
- Trial name
- NCT02151786
- Testing
- Lansoprazole
- Volunteers
- 1,120 people
- Sponsor
- Takeda
Leukemia, Lymphoma
Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00278161
- Testing
- Pegfilgrastim, Rituximab, Cyclophosphamide
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Multiple Myeloma
UARK 2009-09 Myeloma Cure Project: Prospective Trial of Indefinite Revlimid Maintenance Versus Observation for Currently Event-Free Patients With Multiple Myeloma
The purpose of this study is to determine in a phase II trial, whether further maintenance therapy with Revlimid can extend the duration of progression-free survival and the duration of complete or near complete response compared…
- Trial name
- NCT01621672
- Testing
- Revlimid
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Arkansas
Multiple Myeloma
A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Treated Multiple Myeloma
Randomized, open-label, international, multi-center, Phase 3 study in which patients are randomized to receive VELCADE administered by subcutaneous injection or intravenous infusion.
- Trial name
- NCT00722566
- Testing
- VELCADE Administered by subcutaneous injection, VELCADE Administered by intravenous infusion
- Where
- 3 sites in Belgium, France and 1 more
- Volunteers
- 222 people
- Sponsor
- Millennium Pharmaceuticals, Inc.